-

SHAREHOLDER ALERT: Robbins LLP Announces That Ebang International Holdings Inc. (EBON) is Being Sued for Misleading Shareholders

SAN DIEGO & HANGZHOU, China--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Ebang International Holdings Inc. (NASDAQ: EBON) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between June 26, 2020 and April 5, 2021. Ebang purports to be a leading application-specific integrated circuit ("ASIC") chip design company and a leading manufacturer of Bitcoin mining machines.

If you suffered a loss due to Ebang Holdings Inc.'s misconduct, click here.

Ebang International Holdings Inc. (EBON) Misled Investors Regarding its Business Plan

According to the complaint, during the class period, Ebang failed to disclose to investors that: (i) the proceeds from Ebang's initial public offering ("IPO") in November 2020 had been direct to related parties instead of the Company's operations; (ii) Ebang had inflated reported sales, including through defective units; and (iii) its attempts to go public in Hong Kong had failed due to allegations of embezzling investor funds and inflated sales figures.

On April 6, 2021, before the market opened, Hindenburg Research reported that Ebang is directing proceeds from its IPO into a "series of opaque deals with insiders and questionable counterparties." According to the report, Ebang raised $21 million, claiming the proceeds would go "primarily for development," but instead used the funds to repay related-party loans to a relative of Ebang's CEO, Dong Hu. The report also noted that Ebang failed to go public on the Hong Kong Stock Exchange due to a sales inflation scheme with Yindou, a Chinese peer-to-peer online lending platform that defrauded 20,000 retail investors in 2018 with $655 million "vanish[ing] into thin air." The report also challenged Ebang's claim to be the leading bitcoin producer globally and noted that the Company's sales appeared to be "defective units or just fabricated altogether."

On this news, Ebang's stock price fell approximately 13%, to close at $5.53 per share on April 6, 2021. In response, Ebang issued a statement that it believed the report "contain[ed] many errors, unsupported speculations and inaccurate interpretations of events," and indicated that the Board and Audit Committee would review the allegations. The Company's stock price declined further on this news.

If you purchased shares of Ebang International Holdings Inc. (EBON) between June 26, 2020 and April 5, 2021, you have until June 7, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Ebang International Holdings Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom